FIELD: pharmaceutical industry.
SUBSTANCE: albumin-binding prodrugs derived from auristatin E, which can be used for the treatment of malignant diseases.
EFFECT: reduction in cytotoxicity compared to an equivalent dose of the unmodified active agent.
18 cl, 25 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DRUG DELIVERY SYSTEMS BASED ON MAYTANSINOID | 2018 |
|
RU2783076C2 |
| DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | 2016 |
|
RU2748992C2 |
| IMAGING MEANS FOR RADIOLABELED EXOGENOUS AND ENDOGENOUS ALBUMIN | 2019 |
|
RU2819907C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING NANOPARTICLES CONTAINING INSOLUBLE COMPOUND BASED ON CAMPTOTHECIN FOR TREATING CANCER, AND COMBINATION THERAPY USING THEREOF | 2021 |
|
RU2827894C1 |
| RADIOACTIVE LABELLED PEPTIDES BINDING TO HER2 | 2011 |
|
RU2592685C2 |
| MONOMETHYL AURISTATIN E CONJUGATE FOR PREPARING A COMPOSITION FOR TREATING PROSTATE CANCER | 2019 |
|
RU2729192C1 |
| VACCINE COMPOSITIONS | 2010 |
|
RU2581020C2 |
| ANTICANCER PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATING BREAST CANCER | 2015 |
|
RU2581022C1 |
| PHARMACEUTICAL COMPOSITIONS OF SAPOSIN C AND METHODS FOR TREATING CANCER | 2018 |
|
RU2767199C1 |
| STABLE PHARMACEUTICAL PREPARATION BASED ON THE PD-1 ANTIBODY AND ITS USE IN MEDICINE | 2016 |
|
RU2731418C2 |
Authors
Dates
2023-04-28—Published
2018-11-30—Filed